Amgen 2004 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2004 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

1986
George B.
Rathmann named
chairman of
Amgen’s Board
of Directors
1987
Amgen receives
fi rst patent
relating to DNA
used in producing
EPOGEN®
1989
Amgen receives
fi rst patent for
recombinant G-CSF
(NEUPOGEN®)
FDA approves
EPOGEN® for
the treatment
of anemia in adult
patients with
chronic renal
failure who
are on dialysis
Immunex discovers
and fi les a patent
application on a
new TNF receptor
that will be
developed to become
ENBREL® (etanercept)
Amgen enters
Europe, establishing
European
headquarters in
Lucerne, Switzerland,
and a development
organization in
Cambridge, U.K.
EPOGEN® named
“Product of the Year”
by Fortune magazine
1990
George B.
Rathmann
retires
Gordon M.
Binder named
chairman of
Amgen’s Board
of Directors
1980
– 1991
1991
Regulators in the
U.S., Canada, Europe
and Australia approve
NEUPOGEN® to
decrease the incidence
of infection associated
with chemotherapy-
induced neutropenia
in patients with non-
myeloid cancers
receiving myelo-
suppressive therapy
Amgen establishes the
Amgen Foundation
for charitable giving
Amgen opens
subsidiaries in
Australia and Canada
NEUPOGEN®
named “Product
of the Year” by
Fortune magazine
1988
Gordon M. Binder
named chief
executive offi cer
Amgen 2004 Annual Report page 19